TY - JOUR
T1 - Phase I study of elliptinium (2-n-methyl-9-hydroxyellipticinium)
AU - Einzig, Avi I.
AU - Gralla, Richard J.
AU - Leyland-Jones, Brian R.
AU - Kelsen, David P.
AU - Cibas, Irene
AU - Lewis, Ellen
AU - Greenberg, And Ernest
N1 - Funding Information:
This work was supported by Ives Laboratories Inc. and National Cancer Institute Grant CA-05826.
PY - 1985
Y1 - 1985
N2 - Elliptinium (2-N-methyl-9-hydroxyellipticinium), a chemotherapeutic agent whose mechanism of action has not been completely elucidated, intercalates into DNA. In this Phase I clinical trial, the schedule of drug administration consisted of weekly intravenous infusions. Twenty-nine patients were evaluable for toxicity. The initial dose level was 40 mg/m2 and was escalated to 150 mg/m2 through six levels. The dose-limiting side effects were emesis, xerostomia, and azotemia. The lack of myelosuppression was the most striking feature. Objective responses (partial remission, minor response) were seen in one patient each with Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, and nasopharyngeal carcinoma. We recommend a Phase II evaluation of elliptinium at a dose of 100 mg/m2 on a weekly schedule.
AB - Elliptinium (2-N-methyl-9-hydroxyellipticinium), a chemotherapeutic agent whose mechanism of action has not been completely elucidated, intercalates into DNA. In this Phase I clinical trial, the schedule of drug administration consisted of weekly intravenous infusions. Twenty-nine patients were evaluable for toxicity. The initial dose level was 40 mg/m2 and was escalated to 150 mg/m2 through six levels. The dose-limiting side effects were emesis, xerostomia, and azotemia. The lack of myelosuppression was the most striking feature. Objective responses (partial remission, minor response) were seen in one patient each with Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, and nasopharyngeal carcinoma. We recommend a Phase II evaluation of elliptinium at a dose of 100 mg/m2 on a weekly schedule.
UR - http://www.scopus.com/inward/record.url?scp=0022256969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022256969&partnerID=8YFLogxK
U2 - 10.3109/07357908509039784
DO - 10.3109/07357908509039784
M3 - Article
C2 - 4005651
AN - SCOPUS:0022256969
SN - 0735-7907
VL - 3
SP - 235
EP - 241
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -